Remaining $5.4 million debt was repaid through strategic equity conversion in common stock with no additional warrants or adjustment provisions Company anticipates that Dec 31 balance sheet will ...

NRx is developing treatments for central nervous system disorders including suicidal depression, chronic pain, and PTSD. Its lead candidates include NRX-100, an intravenous ketamine formulation that ...

WILMINGTON, DE — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) said the U.S. Food and Drug Administration has accepted its Abbreviated New Drug Application for KETAFREE, a preservative-free intravenous ...

The latest price target for NRX Pharmaceuticals (NASDAQ:NRXP) was reported by Ascendiant Capital on January 2, 2026. The analyst firm set a price target for $48.00 expecting NRXP to rise to within 12 ...

December 2, 2025 • After a decade of development, Metroid Prime 4: Beyond is a beautiful but befuddling game full of misguided design decisions and annoying sidekicks. November 19, 2025 • Simple ...

With more than three years of experience as a personal finance writer, Jamela Adam simplifies complex money topics to help readers become experts at managing their finances. Her work has been featured ...

Jennifer Simonson is a business journalist with a decade of experience covering entrepreneurship and small business. Drawing on her background as a founder of multiple startups, she writes for Forbes ...

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, said the FDA has received its Abbreviated New Drug Application for KETAFREE(TM), a preservative-free intravenous ...

We independently review everything we recommend. When you buy through our links, we may earn a commission. Learn more› By Jackie Reeve Jackie Reeve is a writer covering all things bedding. She has ...

We independently review everything we recommend. When you buy through our links, we may earn a commission. Learn more› By Lesley Stockton Lesley Stockton is a writer focused on kitchen and ...